Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Anthera Pharmaceuticals Inc : Faruqi & Faruqi, LLP is Investigating Anthera Pharmaceuticals Incorporated on Behalf of its Shareholders - ANTH

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/13/2013 | 02:05pm CET

NEW YORK, Feb. 13, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and the enforcement of federal antitrust laws, is investigating potential claims against the board of directors of Anthera Pharmaceuticals Incorporated ("Anthera" or the "Company") (Nasdaq: ANTH) concerning possible breaches of fiduciary duty and other violations of law related to the Company's compensation packages for its executive officers. The investigation focuses on the approval and awarding of certain stock options to executives that may have violated the Company's compensation plans.

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO)

Request more information now by clicking here: www.faruqilaw.com/ANTH

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action and derivative litigation. The firm is focused on providing exemplary legal services in the areas of securities, shareholder, antitrust and consumer litigation, through all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients.

If you hold ANTH shares and you would like to discuss your legal rights, visit www.faruqilaw.com/ANTH. You can also contact us by calling Michael J. Hynes free at 877-247-4292 or at 215-277-5770 or by sending an e-mail to mhynes@faruqilaw.com.

Contact:

Faruqi & Faruqi, LLP
Michael J. Hynes, Esq.
101 Greenwood Avenue Suite 600
Jenkintown, PA 19046
Telephone: (877) 247-4292 or (215) 277-5770
E-mail: mhynes@faruqilaw.com

(Nasdaq: ANTH)

Attorney Advertising. (C) 2013 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ANTA PHAR
02/17 ROBBINS ARROYO LLP : Anthera Pharmaceuticals, Inc. (ANTH) Misled Shareholders Ac..
02/17 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Notice of Delisting or..
02/16 ANTHERA PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Contin..
01/17 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Anthera Pharmac..
01/13 Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violatio..
01/08 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Regulation FD Disclosu..
01/06 ANTHERA PHARMACEUTICALS INC : Regulation FD Disclosure (form 8-K)
2016 WEDNESDAY SECTOR LAGGARDS : Music & Electronics Stores, Biotechnology Stocks
2016 ANTHERA PHARMACEUTICALS : ANTH) Falls on Missing Endpoint
2016 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Other Events
More news
Sector news : Bio Therapeutic Drugs
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
More sector news : Bio Therapeutic Drugs